- First tranche of $15 million expected to close on March 20, 2026; second tranche of up to $15 million available, for up to $30 million in total proceeds from the sale of common stock and pre-funded warrants priced at $2.25 per share, representing a 68% premium to the March 17, 2026 closing price.

- Financing includes 50% warrant coverage priced at $5 per share, representing a 273% premium to market, if exercised would raise up to an additional $33.3 million, extending runway into 2H 2027.

- Proceeds to support ongoing single-ascending dose (SAD) registrational study arm under 505(b)(2) NDA pathway.